Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients
Abstract Pseudomonas aeruginosa frequently infects the respiratory tract of cystic fibrosis (CF) patients. Multidrug-resistant phenotypes and high capacity to form stable biofilms are common. Recent studies have described the emergence of colistin-resistant isolates in CF patients treated with long-...
Gespeichert in:
| Veröffentlicht in: | Journal of cystic fibrosis 2016-09, Vol.15 (5), p.611-618 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 618 |
|---|---|
| container_issue | 5 |
| container_start_page | 611 |
| container_title | Journal of cystic fibrosis |
| container_volume | 15 |
| creator | Sans-Serramitjana, E Fusté, E Martínez-Garriga, B Merlos, A Pastor, M Pedraz, J.L Esquisabel, A Bachiller, D Vinuesa, T Viñas, M |
| description | Abstract Pseudomonas aeruginosa frequently infects the respiratory tract of cystic fibrosis (CF) patients. Multidrug-resistant phenotypes and high capacity to form stable biofilms are common. Recent studies have described the emergence of colistin-resistant isolates in CF patients treated with long-term inhaled colistin. The use of nanoparticles containing antimicrobials can contribute to overcome drug resistance mechanisms. The aim of this study was to explore antimicrobial activity of nanoencapsulated colistin (SLN-NLC) versus free colistin against P. aeruginosa clinical isolates from CF patients and to investigate their efficacy in biofilm eradication. Susceptibility of planktonic bacteria to antimicrobials was examined by using the broth microdilution method and growth curve assay. Minimal biofilm eradication concentration (MBEC) and biofilm prevention concentration (BPC) were determined to assess antimicrobial susceptibility of sessile bacteria. We used atomic force microscopy (AFM) to visualize treated and untreated biofilms and to determine surface roughness and other relevant parameters. Colistin nanoparticles had the same antimicrobial activity as free drug against planktonic bacteria. However, nanoencapsulated colistin was much more efficient in the eradication of biofilms than free colistin. Thus, these formulations have to be considered as a good alternative therapeutic option to treat P. aeruginosa infections. |
| doi_str_mv | 10.1016/j.jcf.2015.12.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1817845274</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1569199315002775</els_id><sourcerecordid>1817845274</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-96d73b4dc266605f361d6e8d86ca84e3e83b279e2a670e37f2f1fd5c4eb40e393</originalsourceid><addsrcrecordid>eNp9kU-L1TAUxYMozjj6AdxIlm5ac9MmaREEGfyHAwrqOqTJzZBOmzyTVnjf3jze6MKFqySXcw65v0PIc2AtMJCv5na2vuUMRAu8ZUw8IJcwqK4RDNjDehdybGAcuwvypJSZMVBMDY_JBZeKDVyKS3L3OSxLiLcUvUe70eRpNDFhtOZQ9sVs6KhNSyhbiLQOfJ3QFOnXgrtLa4qmUIN5vw0xFUN9Tiu1x6q21IcppxIKPZgtYNzKU_LIm6Xgs_vzivx4_-779cfm5suHT9dvbxrbC9iaUTrVTb2zXErJhO8kOImDG6Q1Q48dDt3E1Yjc1C2wU5578E7YHqe-vsfuirw85x5y-rlj2fQaisVlMRHTXjQMoIZecNVXKZyltn61ZPT6kMNq8lED0yfGetaVsT4x1sB1ZVw9L-7j92lF99fxB2oVvD4LsC75K2DWxVYAFl3IlbF2Kfw3_s0_blsLCtYsd3jEMqc9x0pPgy7VoL-dSj51DIIxrpTofgMs2qNt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1817845274</pqid></control><display><type>article</type><title>Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Sans-Serramitjana, E ; Fusté, E ; Martínez-Garriga, B ; Merlos, A ; Pastor, M ; Pedraz, J.L ; Esquisabel, A ; Bachiller, D ; Vinuesa, T ; Viñas, M</creator><creatorcontrib>Sans-Serramitjana, E ; Fusté, E ; Martínez-Garriga, B ; Merlos, A ; Pastor, M ; Pedraz, J.L ; Esquisabel, A ; Bachiller, D ; Vinuesa, T ; Viñas, M</creatorcontrib><description>Abstract Pseudomonas aeruginosa frequently infects the respiratory tract of cystic fibrosis (CF) patients. Multidrug-resistant phenotypes and high capacity to form stable biofilms are common. Recent studies have described the emergence of colistin-resistant isolates in CF patients treated with long-term inhaled colistin. The use of nanoparticles containing antimicrobials can contribute to overcome drug resistance mechanisms. The aim of this study was to explore antimicrobial activity of nanoencapsulated colistin (SLN-NLC) versus free colistin against P. aeruginosa clinical isolates from CF patients and to investigate their efficacy in biofilm eradication. Susceptibility of planktonic bacteria to antimicrobials was examined by using the broth microdilution method and growth curve assay. Minimal biofilm eradication concentration (MBEC) and biofilm prevention concentration (BPC) were determined to assess antimicrobial susceptibility of sessile bacteria. We used atomic force microscopy (AFM) to visualize treated and untreated biofilms and to determine surface roughness and other relevant parameters. Colistin nanoparticles had the same antimicrobial activity as free drug against planktonic bacteria. However, nanoencapsulated colistin was much more efficient in the eradication of biofilms than free colistin. Thus, these formulations have to be considered as a good alternative therapeutic option to treat P. aeruginosa infections.</description><identifier>ISSN: 1569-1993</identifier><identifier>EISSN: 1873-5010</identifier><identifier>DOI: 10.1016/j.jcf.2015.12.005</identifier><identifier>PMID: 26708265</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - pharmacokinetics ; Antimicrobial effect ; Biofilms - drug effects ; Child ; Colistin - administration & dosage ; Colistin - pharmacokinetics ; Colistin sulfate ; Cystic fibrosis ; Cystic Fibrosis - diagnosis ; Cystic Fibrosis - epidemiology ; Cystic Fibrosis - microbiology ; Cystic Fibrosis - therapy ; Drug Delivery Systems - methods ; Drug Monitoring - methods ; Drug Resistance, Bacterial - drug effects ; Female ; Humans ; Lipid nanoparticles ; Male ; Middle Aged ; Nanoparticles - administration & dosage ; Outcome Assessment (Health Care) ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - isolation & purification ; Pseudomonas aeruginosa - physiology ; Pseudomonas Infections - diagnosis ; Pseudomonas Infections - drug therapy ; Pulmonary/Respiratory ; Respiratory System - microbiology ; Respiratory Tract Infections - diagnosis ; Respiratory Tract Infections - drug therapy ; Respiratory Tract Infections - microbiology ; Spain - epidemiology</subject><ispartof>Journal of cystic fibrosis, 2016-09, Vol.15 (5), p.611-618</ispartof><rights>2015 European Cystic Fibrosis Society.</rights><rights>Copyright © 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-96d73b4dc266605f361d6e8d86ca84e3e83b279e2a670e37f2f1fd5c4eb40e393</citedby><cites>FETCH-LOGICAL-c451t-96d73b4dc266605f361d6e8d86ca84e3e83b279e2a670e37f2f1fd5c4eb40e393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jcf.2015.12.005$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26708265$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sans-Serramitjana, E</creatorcontrib><creatorcontrib>Fusté, E</creatorcontrib><creatorcontrib>Martínez-Garriga, B</creatorcontrib><creatorcontrib>Merlos, A</creatorcontrib><creatorcontrib>Pastor, M</creatorcontrib><creatorcontrib>Pedraz, J.L</creatorcontrib><creatorcontrib>Esquisabel, A</creatorcontrib><creatorcontrib>Bachiller, D</creatorcontrib><creatorcontrib>Vinuesa, T</creatorcontrib><creatorcontrib>Viñas, M</creatorcontrib><title>Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients</title><title>Journal of cystic fibrosis</title><addtitle>J Cyst Fibros</addtitle><description>Abstract Pseudomonas aeruginosa frequently infects the respiratory tract of cystic fibrosis (CF) patients. Multidrug-resistant phenotypes and high capacity to form stable biofilms are common. Recent studies have described the emergence of colistin-resistant isolates in CF patients treated with long-term inhaled colistin. The use of nanoparticles containing antimicrobials can contribute to overcome drug resistance mechanisms. The aim of this study was to explore antimicrobial activity of nanoencapsulated colistin (SLN-NLC) versus free colistin against P. aeruginosa clinical isolates from CF patients and to investigate their efficacy in biofilm eradication. Susceptibility of planktonic bacteria to antimicrobials was examined by using the broth microdilution method and growth curve assay. Minimal biofilm eradication concentration (MBEC) and biofilm prevention concentration (BPC) were determined to assess antimicrobial susceptibility of sessile bacteria. We used atomic force microscopy (AFM) to visualize treated and untreated biofilms and to determine surface roughness and other relevant parameters. Colistin nanoparticles had the same antimicrobial activity as free drug against planktonic bacteria. However, nanoencapsulated colistin was much more efficient in the eradication of biofilms than free colistin. Thus, these formulations have to be considered as a good alternative therapeutic option to treat P. aeruginosa infections.</description><subject>Adult</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Antimicrobial effect</subject><subject>Biofilms - drug effects</subject><subject>Child</subject><subject>Colistin - administration & dosage</subject><subject>Colistin - pharmacokinetics</subject><subject>Colistin sulfate</subject><subject>Cystic fibrosis</subject><subject>Cystic Fibrosis - diagnosis</subject><subject>Cystic Fibrosis - epidemiology</subject><subject>Cystic Fibrosis - microbiology</subject><subject>Cystic Fibrosis - therapy</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Monitoring - methods</subject><subject>Drug Resistance, Bacterial - drug effects</subject><subject>Female</subject><subject>Humans</subject><subject>Lipid nanoparticles</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nanoparticles - administration & dosage</subject><subject>Outcome Assessment (Health Care)</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - isolation & purification</subject><subject>Pseudomonas aeruginosa - physiology</subject><subject>Pseudomonas Infections - diagnosis</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Pulmonary/Respiratory</subject><subject>Respiratory System - microbiology</subject><subject>Respiratory Tract Infections - diagnosis</subject><subject>Respiratory Tract Infections - drug therapy</subject><subject>Respiratory Tract Infections - microbiology</subject><subject>Spain - epidemiology</subject><issn>1569-1993</issn><issn>1873-5010</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU-L1TAUxYMozjj6AdxIlm5ac9MmaREEGfyHAwrqOqTJzZBOmzyTVnjf3jze6MKFqySXcw65v0PIc2AtMJCv5na2vuUMRAu8ZUw8IJcwqK4RDNjDehdybGAcuwvypJSZMVBMDY_JBZeKDVyKS3L3OSxLiLcUvUe70eRpNDFhtOZQ9sVs6KhNSyhbiLQOfJ3QFOnXgrtLa4qmUIN5vw0xFUN9Tiu1x6q21IcppxIKPZgtYNzKU_LIm6Xgs_vzivx4_-779cfm5suHT9dvbxrbC9iaUTrVTb2zXErJhO8kOImDG6Q1Q48dDt3E1Yjc1C2wU5578E7YHqe-vsfuirw85x5y-rlj2fQaisVlMRHTXjQMoIZecNVXKZyltn61ZPT6kMNq8lED0yfGetaVsT4x1sB1ZVw9L-7j92lF99fxB2oVvD4LsC75K2DWxVYAFl3IlbF2Kfw3_s0_blsLCtYsd3jEMqc9x0pPgy7VoL-dSj51DIIxrpTofgMs2qNt</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Sans-Serramitjana, E</creator><creator>Fusté, E</creator><creator>Martínez-Garriga, B</creator><creator>Merlos, A</creator><creator>Pastor, M</creator><creator>Pedraz, J.L</creator><creator>Esquisabel, A</creator><creator>Bachiller, D</creator><creator>Vinuesa, T</creator><creator>Viñas, M</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160901</creationdate><title>Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients</title><author>Sans-Serramitjana, E ; Fusté, E ; Martínez-Garriga, B ; Merlos, A ; Pastor, M ; Pedraz, J.L ; Esquisabel, A ; Bachiller, D ; Vinuesa, T ; Viñas, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-96d73b4dc266605f361d6e8d86ca84e3e83b279e2a670e37f2f1fd5c4eb40e393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Antimicrobial effect</topic><topic>Biofilms - drug effects</topic><topic>Child</topic><topic>Colistin - administration & dosage</topic><topic>Colistin - pharmacokinetics</topic><topic>Colistin sulfate</topic><topic>Cystic fibrosis</topic><topic>Cystic Fibrosis - diagnosis</topic><topic>Cystic Fibrosis - epidemiology</topic><topic>Cystic Fibrosis - microbiology</topic><topic>Cystic Fibrosis - therapy</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Monitoring - methods</topic><topic>Drug Resistance, Bacterial - drug effects</topic><topic>Female</topic><topic>Humans</topic><topic>Lipid nanoparticles</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nanoparticles - administration & dosage</topic><topic>Outcome Assessment (Health Care)</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - isolation & purification</topic><topic>Pseudomonas aeruginosa - physiology</topic><topic>Pseudomonas Infections - diagnosis</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Pulmonary/Respiratory</topic><topic>Respiratory System - microbiology</topic><topic>Respiratory Tract Infections - diagnosis</topic><topic>Respiratory Tract Infections - drug therapy</topic><topic>Respiratory Tract Infections - microbiology</topic><topic>Spain - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sans-Serramitjana, E</creatorcontrib><creatorcontrib>Fusté, E</creatorcontrib><creatorcontrib>Martínez-Garriga, B</creatorcontrib><creatorcontrib>Merlos, A</creatorcontrib><creatorcontrib>Pastor, M</creatorcontrib><creatorcontrib>Pedraz, J.L</creatorcontrib><creatorcontrib>Esquisabel, A</creatorcontrib><creatorcontrib>Bachiller, D</creatorcontrib><creatorcontrib>Vinuesa, T</creatorcontrib><creatorcontrib>Viñas, M</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cystic fibrosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sans-Serramitjana, E</au><au>Fusté, E</au><au>Martínez-Garriga, B</au><au>Merlos, A</au><au>Pastor, M</au><au>Pedraz, J.L</au><au>Esquisabel, A</au><au>Bachiller, D</au><au>Vinuesa, T</au><au>Viñas, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients</atitle><jtitle>Journal of cystic fibrosis</jtitle><addtitle>J Cyst Fibros</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>15</volume><issue>5</issue><spage>611</spage><epage>618</epage><pages>611-618</pages><issn>1569-1993</issn><eissn>1873-5010</eissn><abstract>Abstract Pseudomonas aeruginosa frequently infects the respiratory tract of cystic fibrosis (CF) patients. Multidrug-resistant phenotypes and high capacity to form stable biofilms are common. Recent studies have described the emergence of colistin-resistant isolates in CF patients treated with long-term inhaled colistin. The use of nanoparticles containing antimicrobials can contribute to overcome drug resistance mechanisms. The aim of this study was to explore antimicrobial activity of nanoencapsulated colistin (SLN-NLC) versus free colistin against P. aeruginosa clinical isolates from CF patients and to investigate their efficacy in biofilm eradication. Susceptibility of planktonic bacteria to antimicrobials was examined by using the broth microdilution method and growth curve assay. Minimal biofilm eradication concentration (MBEC) and biofilm prevention concentration (BPC) were determined to assess antimicrobial susceptibility of sessile bacteria. We used atomic force microscopy (AFM) to visualize treated and untreated biofilms and to determine surface roughness and other relevant parameters. Colistin nanoparticles had the same antimicrobial activity as free drug against planktonic bacteria. However, nanoencapsulated colistin was much more efficient in the eradication of biofilms than free colistin. Thus, these formulations have to be considered as a good alternative therapeutic option to treat P. aeruginosa infections.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26708265</pmid><doi>10.1016/j.jcf.2015.12.005</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1569-1993 |
| ispartof | Journal of cystic fibrosis, 2016-09, Vol.15 (5), p.611-618 |
| issn | 1569-1993 1873-5010 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1817845274 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - pharmacokinetics Antimicrobial effect Biofilms - drug effects Child Colistin - administration & dosage Colistin - pharmacokinetics Colistin sulfate Cystic fibrosis Cystic Fibrosis - diagnosis Cystic Fibrosis - epidemiology Cystic Fibrosis - microbiology Cystic Fibrosis - therapy Drug Delivery Systems - methods Drug Monitoring - methods Drug Resistance, Bacterial - drug effects Female Humans Lipid nanoparticles Male Middle Aged Nanoparticles - administration & dosage Outcome Assessment (Health Care) Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas aeruginosa - isolation & purification Pseudomonas aeruginosa - physiology Pseudomonas Infections - diagnosis Pseudomonas Infections - drug therapy Pulmonary/Respiratory Respiratory System - microbiology Respiratory Tract Infections - diagnosis Respiratory Tract Infections - drug therapy Respiratory Tract Infections - microbiology Spain - epidemiology |
| title | Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T12%3A05%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Killing%20effect%20of%20nanoencapsulated%20colistin%20sulfate%20on%20Pseudomonas%20aeruginosa%20from%20cystic%20fibrosis%20patients&rft.jtitle=Journal%20of%20cystic%20fibrosis&rft.au=Sans-Serramitjana,%20E&rft.date=2016-09-01&rft.volume=15&rft.issue=5&rft.spage=611&rft.epage=618&rft.pages=611-618&rft.issn=1569-1993&rft.eissn=1873-5010&rft_id=info:doi/10.1016/j.jcf.2015.12.005&rft_dat=%3Cproquest_cross%3E1817845274%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1817845274&rft_id=info:pmid/26708265&rft_els_id=S1569199315002775&rfr_iscdi=true |